Reasons for Discontinuation of dupilumab in Adult Atopic Dermatitis in Clinical Practice.

Date publication

novembre 2021

Journal

The British journal of dermatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François

Tous les auteurs :
Marniquet ME, Seneschal J, Darrigade AS, Staumont-Sallé D, Jachiet M, Nosbaum A, Tauber M, Abasq C, Ferrier Le Bouedec MC, Droitcourt C, Aubert H, Bernier C, Soria A, Raison-Peyron N, Tétart F, Aubin F, Viguier M, Valois A, Kupfer-Bessaguet I, Goronflot T, Barbarot S,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34748654

Résumé

Dupilumab, an anti-IL-4ɑ monoclonal antibody, has shown a positive benefit-risk ratio when treating moderate to severe atopic dermatitis (AD) in clinical studies (1). High persistence on dupilumab has recently been reported in clinical-practice setting with 77% of patients remaining in treatment for 12 months in a retrospective study including 1,963 patients with AD but reasons for discontinuation were not investigated (2).

Référence

Br J Dermatol. 2021 Nov 8;: